Why the study?
Does losartan improve left ventricular remodeling in mice with cardiac restricted overexpression of TNF?
Population
Transgenic mice (MHCsTNF) with cardiac restricted overexpression of tumor necrosis factor (TNF)
Comparison
Losartan (30 mg/kg) from 4 to 8 weeks of age vs Diluent from 4 to 8 weeks of age
Design
Preclinical
Follow-up
4 weeks (from 4 to 8 weeks of age)
Authors
Loading...
Attenuates remodeling in TNF-overexpressing mice; leaves open whether RAS-TNF interaction informs human cardiomyopathy therapy.
Does losartan improve left ventricular remodeling in mice with cardiac restricted overexpression of TNF?
Losartan attenuates left ventricular remodeling, myocardial fibrosis, and myocyte apoptosis in a transgenic mouse model of cardiac-restricted TNF overexpression, highlighting a functional interaction between RAS and TNF in the heart.
Flesch et al. (2003) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: